Basilea Pharmaceutica AG (0QNA.L)
0QNA.L Stock Price Chart
Explore Basilea Pharmaceutica AG interactive price chart. Choose custom timeframes to analyze 0QNA.L price movements and trends.
0QNA.L Company Profile
Discover essential business fundamentals and corporate details for Basilea Pharmaceutica AG (0QNA.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
7 Mar 2014
Employees
164.00
Website
https://www.basilea.comCEO
David Veitch
Description
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
0QNA.L Financial Timeline
Browse a chronological timeline of Basilea Pharmaceutica AG corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 16 Feb 2026
Upcoming earnings on 19 Aug 2025
Earnings released on 18 Feb 2025
EPS came in at CHF 4.10 surpassing the estimated CHF 3.24 by +26.54%, while revenue for the quarter reached CHF 132.25M, beating expectations by +4.13%.
Earnings released on 13 Aug 2024
EPS came in at CHF 1.50 surpassing the estimated CHF 1.17 by +28.21%, while revenue for the quarter reached CHF 76.29M, missing expectations by -28.09%.
Earnings released on 24 Apr 2024
EPS came in at -CHF 1.78 surpassing the estimated -CHF 2.01 by +11.11%, while revenue for the quarter reached CHF 72.73M, beating expectations by +1.11%.
Earnings released on 30 Jun 2023
EPS came in at CHF 2.31 surpassing the estimated CHF 0.81 by +186.96%, while revenue for the quarter reached CHF 84.91M, beating expectations by +31.16%.
Earnings released on 31 Dec 2022
EPS came in at CHF 2.04 surpassing the estimated -CHF 1.30 by +256.92%, while revenue for the quarter reached CHF 89.12M, beating expectations by +80.40%.
Earnings released on 30 Jun 2022
EPS came in at -CHF 1.03 surpassing the estimated -CHF 1.55 by +33.47%, while revenue for the quarter reached CHF 58.65M, beating expectations by +38.32%.
Earnings released on 31 Dec 2021
EPS came in at CHF 1.10 surpassing the estimated CHF 0.07 by +1.47K%, while revenue for the quarter reached CHF 93.92M, beating expectations by +10.63%.
Earnings released on 30 Jun 2021
EPS came in at -CHF 1.72 falling short of the estimated -CHF 1.53 by -12.41%, while revenue for the quarter reached CHF 54.20M, missing expectations by -7.67%.
Earnings released on 31 Dec 2020
EPS came in at -CHF 2.27 surpassing the estimated -CHF 2.62 by +13.38%, while revenue for the quarter reached CHF 58.30M, missing expectations by -3.07%.
0QNA.L Stock Performance
Access detailed 0QNA.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.